SCHEMBL2191491

SCHEMBL2191491

CC(C)C[C@@H](C1CC1CCO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)N(Cc1ccccc1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SMYD2 Q9NRG4 3/20 0.38
CTSL P07711 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
PSMB5 P28074 1/20 0.32
ALDH1A1 P00352 2/20 0.31
LMNA P02545 1/20 0.31
POLB P06746 1/20 0.31
HSD17B10 Q99714 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
KDM4E B2RXH2 1/20 0.30
MMP1 P03956 1/20 0.30
MMP3 P08254 1/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2193569 0.87 CYP3A4 (0.40) CYP3A4HTTSMN1; SMN2SMYD2
SCHEMBL2192038 0.79 MEN1 (0.42) CTSLMEN1KMT2AALDH1A1LMNA
SCHEMBL13374068 0.79 SMYD2 (0.42) CYP3A4HTTSMN1; SMN2SMYD2
SCHEMBL14877043 0.79 CYP3A4 (0.41) CYP3A4HTTSMN1; SMN2SMYD2MEN1
SCHEMBL20531233 0.79 CYP3A4 (0.41) CYP3A4HTTSMN1; SMN2SMYD2MEN1
SCHEMBL2190800 0.78 SMYD2 (0.41) CYP3A4HTTSMN1; SMN2SMYD2
SCHEMBL30439364 0.77 CTSK (0.45) CYP3A4CTSL
SCHEMBL30440112 0.76 MEN1 (0.39) CYP3A4HTTSMN1; SMN2SMYD2CTSL
SCHEMBL2191494 0.74 SMN1; SMN2 (0.38) CYP3A4HTTSMN1; SMN2SMYD2MEN1
SCHEMBL2193572 0.72 CYP3A4 (0.39) CYP3A4HTTSMN1; SMN2SMYD2PSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288551-B2 Targeted nitroxide agents UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-10-16 US disclosed
US-20110172214-A1 USE OF TARGETED NITROXIDE AGENTS IN PREVENTING, MITIGATING AND TREATING RADIATION INJURY UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2011-07-14 US disclosed
US-20100035869-A1 TARGETED NITROXIDE AGENTS PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172214-A1 USE OF TARGETED NITROXIDE AGENTS IN PREVENTING, MITIGATING AND TREATING RADIATION INJURY TXNRD2, TXN2, HSPE1 CYP3A4 2111/4885HTT 2621/4885SMN1; SMN2 938/4885
US-20100035869-A1 TARGETED NITROXIDE AGENTS TXNRD2, TXN2, HSPE1 CYP3A4 1585/4885HTT 1855/4885SMN1; SMN2 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.